Synthekine Inc. has established a worldwide collaboration with Sanofi SA to develop and commercialize IL-10 receptor agonists for the treatment of inflammatory diseases.
Tr1x Inc. announced a $75 million series A financing to advance universal allogeneic regulatory T (Treg) and chimeric antigen receptor (CAR)-Treg cell therapies into the clinic to treat autoimmune and inflammatory diseases.
Trex Bio Inc. has announced its selection of a new development candidate, TRB-061, designed to selectively agonize TNF receptor 2 (TNFR2), a mechanism with potential across a broad range of autoimmune indications.
A team from Siemens Medical Solutions Inc. presented a new artificial intelligence (AI) model that can predict people’s risk of multiple sclerosis (MS), at the 2023 American Association for Clinical Chemistry (AACC) annual scientific meeting in Anaheim, Calif.
CD122 signaling plays a key role in the function of CD4, CD8 T cells and natural killer (NK) cells, as well as in the development and survival of tissue-resident memory T cells (TRMs).
UCB SA has identified imidazotriazine derivatives acting as IL-17 modulators reported to be useful for the treatment of autoimmune and inflammatory disorders.
Researchers from Meiji Seika Pharma Co. Ltd. and affiliated organizations reported the discovery and preclinical evaluation of a novel PD-1 agonist antibody, HM-266, being developed for the treatment of various inflammatory disorders, including autoimmune diseases.
A team from the University of Geneva (UNIGE) in Switzerland and the Ludwig Maximilian University of Munich in Germany has succeeded in developing a fully biodegradable nanoparticle able to deliver a new anti-inflammatory drug directly into macrophages where an uncontrolled inflammatory response has been triggered.
